Adam Feuerstein from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion - 5 months ago Listen: 2023 in review, CEO report cards, and a look at the year ahead - 5 months ago STAT+: Here are the worst biopharma CEOs of 2023 - 5 months ago STAT Virtual Event \| Cancer’s Breakthrough Engine - 5 months ago STAT+: Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study - 5 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 5 months ago STAT+: Vertex non-opioid drug reduces chronic nerve pain in mid-stage study - 5 months ago STAT+: Maze CEO ‘personally disappointed’ in Sanofi decision to terminate partnership - 5 months ago STAT+: After sickle-cell screwups, Bluebird Bio’s only option might be a company sale - 5 months ago STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead - 5 months ago In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease - 5 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 6 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 6 months ago STAT+: Argenx antibody fails study in platelet-destroying autoimmune disorder, derailing expansion plans - 6 months ago STAT+: Springworks wins FDA approval for drug to treat desmoid tumors - 6 months ago STAT+: Mixed study results for MorphoSys blood-cancer drug raise questions about approval - 6 months ago Key questions (and answers) about the historic approval of a CRISPR-based medicine - 6 months ago Listen: A CRISPR milestone, algorithms amok, & biotech mixology - 6 months ago STAT+: Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation - 6 months ago STAT+: In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients - 6 months ago Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion - 6 months ago STAT+: Moonlake’s credibility takes another hit with mid-stage study spin job - 7 months ago STAT+: Astellas shows enough data for eye treatment to support expanded use, but still lags competitor - 7 months ago Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO - 7 months ago STAT+: Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial - 7 months ago STAT+: Cassava pulled back the curtain on its Alzheimer’s study — and revealed insurmountable problems - 7 months ago STAT+: FDA has some safety concerns about CRISPR-based sickle cell treatment, documents show - 7 months ago Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise - 7 months ago STAT+: Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show - 7 months ago STAT+: Biogen’s tau-lowering drug slows cognitive decline in early study of Alzheimer’s disease - 7 months ago STAT+: Roivant’s CEO is a star, but even a blockbuster deal can’t escape biotech’s black hole - 7 months ago Listen: Live from the 2023 STAT Summit - 7 months ago STAT+: It’s time for the FDA to halt Cassava Sciences’ Alzheimer’s clinical trials - 7 months ago Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs - 7 months ago STAT+: Akero’s treatment for NASH falls short in cirrhosis study - 7 months ago STAT+: Bristol ‘take-under’ of Mirati is not so great for biotech, but company’s new cancer target has potential - 7 months ago STAT+: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind - 8 months ago
2	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Listen: 2023 in review, CEO report cards, and a look at the year ahead - 5 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 5 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 6 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 6 months ago Listen: A CRISPR milestone, algorithms amok, & biotech mixology - 6 months ago Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion - 6 months ago Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO - 7 months ago Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise - 7 months ago Listen: Live from the 2023 STAT Summit - 7 months ago Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs - 7 months ago
3	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Listen: 2023 in review, CEO report cards, and a look at the year ahead - 5 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 5 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 6 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 6 months ago Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion - 6 months ago Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO - 7 months ago Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise - 7 months ago Listen: Live from the 2023 STAT Summit - 7 months ago Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs - 7 months ago
4	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: Vertex non-opioid drug reduces chronic nerve pain in mid-stage study - 5 months ago
5	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: Mixed study results for MorphoSys blood-cancer drug raise questions about approval - 6 months ago
6	Brittany Trang STAT News Health care business reporter. PhD. Indie rock fan. health carebusiness reporting	Key questions (and answers) about the historic approval of a CRISPR-based medicine - 6 months ago
7	Eric Boodman STAT News	Key questions (and answers) about the historic approval of a CRISPR-based medicine - 6 months ago
8	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	Key questions (and answers) about the historic approval of a CRISPR-based medicine - 6 months ago
9	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Sarepta’s Duchenne gene therapy fails to meet primary endpoint in pivotal trial - 7 months ago
10	Megan Molteni STAT News	STAT+: FDA has some safety concerns about CRISPR-based sickle cell treatment, documents show - 7 months ago